Clinical Trials
13 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04595747 2026-05-22
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00265798 2026-04-28
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT01560260 2018-09-21
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112463 2017-06-14
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030667 2015-04-15
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005874 2013-12-04
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091078 2013-06-05
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00087074 2013-06-04
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025246 2013-02-20
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005862 2013-02-11
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed